Glaxosmithkline Share News (GSK)

GlaxoSmithKline Granted Europe Marketing Authorisation For Relvar Ellipta

DIRECTOR DEALINGS: GlaxoSmithKline Executives Allocated Additional American Depositary Shares

Last-line antibiotics losing ability to kill superbugs in EU

* ECDC survey shows rise in carbapenem resistance * Problem most acute in southern Europe * Health experts urge prudent drug use, more research By Ben Hirschler LONDON, Nov 15 (Reuters) - Europe faces a growing threat from superbugs that are resistant to a powerful, last-r

CORRECTED-Merck invests $107 million in China drug plant

(Corrects company name and RIC to Merck KGaA in para 1, deletes reference to Merck in para 6) * China market could by world's second-biggest by 2016 * Healthcare spending forecast to hit $1 trillion by 2020 * Major drug companies investigated on pricing, corruption * Inter

UPDATE 2-Sarepta shares plunge 60 pct after FDA questions drug trial

* FDA questions drug trial design, says approval application premature * FDA suggests company may need to do larger trial * Analysts say there's almost no chance of an early approval * At least three brokerages downgrade stock * Stock drop wipes off $750 mln of Sarepta's m

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares

Broker tips: RBS, Vodafone, GlaxoSmithKline

Analysts at Goldman Sachs have a positive view on the strategy outlined by Royal Bank of Scotland alongside its third-quarter results. However, the group's new target for common Tier-1 equity, of over 12% versus over 10% before, means that there is now reduced upside potential in RBS shares, "towar

Broker snap: Panmure downgrades GSK after heart drug failure

Broker Panmure Gordon downgraded GlaxoSmithKline after its heart drug Darapaldib, 'the great white hope in the pipeline', failed to reach its primary end-point in a late-stage trial. Analyst Savvas Neophytou trimmed his forecasts, mainly assuming a £150m writedown in the fourth quarter even though

Sarepta says FDA raises doubt about drug trial, shares drop 39 pct

Nov 12 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had raised concerns about the trial for the company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature. Sarepta shares fell 39 percent to $22.20

UK WINNERS & LOSERS: CRH Leads FTSE 100 Winners, John Menzies Dives

UPDATE 2-GlaxoSmithKline heart drug misses goal in major study

* Darapladib misses primary endpoint in Phase III trial * GSK says some success in secondary goals needs analysis * Expectations had been low for new type of heart medicine * Shares fall 1.2 percent By Ben Hirschler LONDON, Nov 12 (Reuters) - An experimental GlaxoSmi

BROKER RATING CHANGES: Goldman Cuts RBS To Neutral From Buy

Tuesday broker round-up UPDATE

Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu

GlaxoSmithKline Hit After Poor Study Results For Heart Disease Drug

London open: Stocks fall ahead of UK inflation data

- Markets eye inflation data - BoE Inflation Report due tomorrow - Corporate earnings come in mixed techMARK 2,636.87 -0.14% FTSE 100 6,706.83 -0.32% FTSE 250 15,395.24 -0.16% UK markets opened lower on Tuesday morning as investors refrained from building positions ahead of domestic inflation data